Your browser is no longer supported. Please, upgrade your browser.
ORIC Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.59 Insider Own1.16% Shs Outstand30.32M Perf Week4.20%
Market Cap1.39B Forward P/E- EPS next Y-2.14 Insider Trans0.00% Shs Float18.11M Perf Month21.49%
Income-53.80M PEG- EPS next Q-0.46 Inst Own97.00% Short Float18.88% Perf Quarter6.87%
Sales- P/S- EPS this Y-25.80% Inst Trans28.49% Short Ratio10.92 Perf Half Y44.67%
Book/sh6.08 P/B5.96 EPS next Y41.20% ROA- Target Price44.14 Perf Year-
Cash/sh4.87 P/C7.44 EPS next 5Y- ROE- 52W Range18.60 - 40.81 Perf YTD7.06%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-11.20% Beta-
Dividend %- Quick Ratio27.30 Sales past 5Y- Gross Margin- 52W Low94.84% ATR2.83
Employees60 Current Ratio27.30 Sales Q/Q- Oper. Margin- RSI (14)57.40 Volatility10.31% 8.48%
OptionableYes Debt/Eq0.00 EPS Q/Q75.00% Profit Margin- Rel Volume0.75 Prev Close34.29
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume313.07K Price36.24
Recom1.60 SMA206.98% SMA506.18% SMA20026.11% Volume233,374 Change5.69%
Jan-25-21Downgrade Citigroup Buy → Neutral $34
Aug-13-20Initiated Robert W. Baird Outperform $45
Aug-06-20Upgrade Citigroup Neutral → Buy $35
Aug-03-20Initiated H.C. Wainwright Buy $52
May-19-20Initiated JP Morgan Overweight $40
May-19-20Initiated Jefferies Buy $40
May-19-20Initiated Guggenheim Buy $45
May-19-20Initiated Citigroup Neutral $35
Mar-02-21 06:30AM  
Feb-17-21 12:15PM  
Feb-03-21 04:30PM  
Feb-02-21 04:04AM  
Jan-11-21 06:30AM  
Jan-08-21 10:35AM  
Jan-04-21 06:30AM  
Dec-21-20 06:30AM  
Dec-10-20 04:50PM  
Dec-01-20 08:30AM  
Nov-17-20 04:15PM  
Nov-13-20 06:32AM  
Nov-10-20 04:05PM  
Nov-09-20 06:30AM  
Nov-05-20 04:05PM  
Nov-04-20 10:43AM  
Oct-19-20 04:02PM  
Oct-09-20 06:30AM  
Sep-02-20 04:30PM  
Aug-06-20 03:50PM  
Aug-05-20 04:10PM  
Aug-03-20 10:15PM  
Jun-22-20 09:00AM  
Jun-09-20 04:15PM  
May-27-20 06:30AM  
May-26-20 06:30AM  
May-20-20 04:15PM  
Apr-28-20 04:30PM  
Apr-27-20 04:30PM  
Apr-23-20 08:56PM  
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.